Vickor Medical: Series C Funding Successfully Closed, Fueling a New Chapter with Hundreds of Millions in Capital!
Time:
2024-12-21
Wuhan, China – Vickor Medical Technology Co., Ltd. ("Vickor Medical") has successfully closed its Series C financing round, raising hundreds of millions of Chinese Yuan (RMB). This round was fully led by Bohua Capital, a prominent investment institution based in Liangxi District, Wuxi. The funds will provide substantial support for Vickor Medical’s product R&D, market expansion, and global strategic initiatives.
Since its establishment in July 2018, Vickor Medical has consistently focused on addressing critical unmet clinical needs in cardiovascular medicine, particularly in minimally invasive interventions for heart failure and structural heart disease. Centered on R&D, technical services, manufacturing, and sales, the company is dedicated to building an innovative medical device platform offering comprehensive cardiovascular full-cycle solutions for patients and physicians worldwide.
Growing Market Demand Fuels Vickor Medical’s Momentum
The global cardiovascular medical device market is experiencing rapid growth, characterized by expanding market size and continuous technological innovation. This landscape presents significant opportunities for Vickor Medical. Leveraging its exceptional R&D capabilities and market foresight, the company has successfully launched multiple innovative products, earning widespread industry recognition. This financing will further accelerate the development of new product lines, deepen market penetration, and advance the company’s globalization strategy, positioning Vickor Medical to make a greater impact on improving global cardiovascular care.
Vickor Medical’s product portfolio spans multiple cardiovascular therapeutic areas, including:Atrial Flow Regulators and active devices for heart failure management;PFO Occluders for the prevention of cardioembolic stroke;Transcatheter Aortic Valve Replacement (TAVR) Systems for valvular heart disease;Supporting procedural accessories and consumables.
Notably, the PFO Occluder and related consumables have achieved commercial success.
The Atrial Flow Regulator has received designation under China NMPA’s "Innovative Medical Device Special Review Program" and the U.S. FDA’s "Breakthrough Device" status.
Furthermore, Vickor Medical’s proprietary TAVR system integrates world-class technology, uniquely designed to treat both stenosis and regurgitation. This minimally invasive procedure requires neither general anesthesia nor pacemaker assistance and can be completed in approximately 40 minutes.
Leadership & Investor Perspectives: Collaboration for Breakthroughs
Bohua Capital Investment Team:"Vickor Medical's innovation capabilities and market execution in the cardiovascular device space are impressive. We are confident that through our close partnership and joint efforts, we will achieve even greater milestones in this field."
Mr. Shang Xiaoke, Founder & Chairman, Vickor Medical:"We are honored to receive the recognition and support from Bohua Capital. This investment will provide vital resources to deepen our expertise in cardiovascular medical technology. With renewed determination and an innovative spirit, we will continue advancing medical science to deliver superior care for patients."
Ms. Wang Xueli, Co-founder & CEO, Vickor Medical:"Vickor Medical remains committed to addressing clinical needs in cardiovascular disease, especially minimally invasive interventions for heart failure and structural heart conditions. We will also strengthen collaborations with healthcare institutions, research organizations, and industry partners to build a thriving innovation ecosystem for sustainable progress in cardiovascular care."
Mr. Chen Song, Co-founder & CTO, Vickor Medical:"This financing not only secures our resources but also validates our strategic direction. We will seize this opportunity to intensify R&D, broaden market access, and accelerate our global expansion."
The successful completion of the Series C financing cements Vickor Medical's leadership position in the cardiovascular medical device sector. Looking ahead, the company is poised to relentlessly drive technological innovation, develop increasingly advanced medical products, and contribute significantly to global heart health, guiding the industry toward a brighter future.
©2023 Wuhan Vickor Medical Technology Co., Ltd.
This site already supports IPV6 access | SEO | Business License